HAVCR2 and neoplasm: The blockade of TIM3/Galectin-9 pathway, to potentiate the anti-tumor function of CD8+TILs and eradicate malignant cells has already revolutionized the treatment of many solid tumors [47, 48] while rare in DLBCL.